Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure

Launched by NORTHWESTERN UNIVERSITY · Oct 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying two different medications, methocarbamol and oxybutynin, to see which one is more effective at managing pain and discomfort after a procedure called ureteroscopy, which is often performed to treat kidney stones. After this procedure, patients usually have a small tube called a ureteral stent placed to help keep the ureter open. While this stent can help, it can also cause significant pain and discomfort, leading to many patients needing emergency care. The trial aims to find out if methocarbamol, a muscle relaxant, can provide better relief from these symptoms compared to oxybutynin, a medication used to treat bladder problems.

To be eligible for this study, participants must be between 18 and 80 years old, have kidney stones, and be undergoing ureteroscopy with stent placement. They should also be willing to take certain pain medications during the study and complete some questionnaires. Participants will receive either methocarbamol or oxybutynin along with standard pain relief after the procedure. Throughout the trial, researchers will monitor how well each medication works and any side effects experienced by the patients. This information could help improve pain management for future patients undergoing similar treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women between age 18-80 years who are diagnosed with stones who undergo ureteroscopy and ureteral stent placement.
• • 2. Patients who consent to the procedure will be randomized in 1:1 fashion by RedCAP either to the methocarbamol or oxybutynin arm. All patients will receive standard of care diclofenac, tamsulosin, and pyridium for pain control plus one of the study drugs.
• • 3. Willing to take only diclofenac (or tramadol for patients with contraindication to diclofenac), phenazopyridine, and acetaminophen for post stent placement discomfort.
• • 4. Willing to sign the Informed Consent Form.
• • 5. Able to read, understand, and complete patient questionnaires, pain texts, and medication diary.
• Exclusion Criteria:
• • 1. Active, symptomatic urinary tract infection.
• • 2. Non-stone related ureteral obstruction or stricture.
• • 3. Procedural trauma or significant retained stone burden that could significantly contribute to patient discomfort.
• • 4. Spinal cord injuries (sensory loss due to injury).
• • 5. Non-stone related voiding dysfunction requiring supplemental bladder drainage tubes for more than 24 hours post operatively.
• • 6. Chronic opioid usage for pain.
• • 7. Members of vulnerable patient populations.